Number | P11
| P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 | P10 | P11 | P12 |
---|
Isolates year | 2001 | 2001 | 2002 | 2002 | 2003 | 2003 | 2004 | 2004 | 2001 | 2002 | 2003 | 2004 |
---|
PFGE type | A | B | C | B | A | A | B | D | A | A | E | A |
Carrying-Int I1
| + | + | + | + | + | + | + | + | - | - | - | - |
AN | R2
| R | R | R | R | S | R | R | R | S | R | S |
SAM | R | R | R | R | R | R | R | R | R | R | R | R |
CTZ | S | S | R | S | R | S | R | S | R | S | S | R |
LVF | S | S | S | S | S | S | S | S | S | S | S | S |
IMP | S | S | S | S | S | S | R | S | S | S | R | S |
PIP-TAZ | S | R | S | R | S | R | S | R | S | R | S | S |
CRO | S | S | R | S | R | S | R | S | R | S | S | R |
- Notes:
-
1P number is the Lane number of PFGE study.
-
2S: Susceptible; R: Resistant; I: Belonged to resistant.
-
3The susceptibility tests were performed using the Vitek-2 GN card (Biomerieux, Marcy l'Etoile, France). The results were interpreted using the CLSI breakpoints (Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility testing).
-
4Abbreviation AN: amikacin; SAM: Ampicillin-sulbactam; CTZ: Ceftazidime; LVF: Levofloxacin; IMP: Imipenem-cilastatin; PIP-TAZ: Piperacillin-tazobactam; CRO: Ceftriaxone; colistin and tigecycline and polymyxin B were not provided by Vitek-2 System.